EU/3/22/2663: Orphan designation for the treatment of maple syrup urine disease

Sodium phenylbutyrate

Table of contents


This medicine was designated as an orphan medicine for the treatment of maple syrup urine disease in the European Union on 18 July 2022.

This means that the developer will receive scientific and regulatory support from EMA to advance their medicine to the stage where they can apply for a marketing authorisation.

Orphan designation does not mean the medicine is available or authorised for use. All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.

During the medicine's development, doctors may be able to enrol patients in clinical trials investigating the medicine. For information on ongoing clinical trials in the EU, see:

Key facts

Active substance
Sodium phenylbutyrate
Intended use
Treatment of maple syrup urine disease
Orphan designation status
EU designation number
Date of designation

Renantos Pharmavertriebsgesellschaft mbH
Spielmannsgasse 12
89077 Ulm

Update history

August 2023The sponsor’s address was updated in August 2023.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating